证券日报网讯1月9日，福安药业（300194）在互动平台回答投资者提问时表示，截至12月31日，公司股 东户数为39047户。 ...

Core Viewpoint - Fu'an Pharmaceutical announced the approval of the proposal to change the auditing firm for the fiscal year 2025 during the first extraordinary shareholders' meeting of 2026 [2] Group 1 - The company held its first extraordinary shareholders' meeting of 2026 on January 6 [2] - The proposal regarding the change of the auditing firm was successfully passed [2]

证券代码：300194 证券简称：福安药业 公告编号：2026-001 福安药业（集团）股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1．本次股东会无增加、变更、否决提案的情况； 2．本次股东会不涉及变更以往股东会已通过的决议； 3．本次股东会对中小投资者的表决单独计票，中小投资者指单独或者合计 持有本公司 5%以上股份的股东以外的其他股东，且不包含持有公司股份的公司 董事、高级管理人员； 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间：2026 年 1 月 6 日（星期二）下午 14:30 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2026 年 1 月 6 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过深圳证 券交易所互联网系统投票的具体时间为 2026 年 1 月 6 日上午 9:15 至下午 15:00 期间的任意时间。 本次会议的召集、召开和表决程序符合《公司法》和《公司章程》的规定。 （二）会议出席情况 ...

上海市虹桥路 1591 号虹桥迎宾馆 34 号楼 邮编：200336 Building 34, Hongqiao Guesthouse, 1591 Hongqiao Rd., Shanghai，p.c: 200336 电话：+86 21 68769686 Tel ：+86 21 68769686 传真：+86 21 68769686 Fax：+86 21 68769686 上海东方华银律师事务所 关于福安药业（集团）股份有限公司 2026 年第一次临时股东会 之 法律意见书 致：福安药业（集团）股份有限公司 为出具本法律意见书，本所律师审查了公司提供的本次股东会的相关资料， 包括但不限于公司召开 2026 年第一次临时股东会的通知、公司 2026 年第一次临 时股东会的议程、议案及决议等文件资料，同时听取了公司董事会秘书就有关事 实的陈述和说明。公司已向本所作出保证和承诺，保证公司向本所提供的资料和 1 东方华银关于福安药业 2026 年第一次临时股东会之法律意见书 文件均为真实、准确、完整，无重大遗漏。 在本法律意见书中，本所律师仅对本次股东会的召集、召开程序、出席会议 人员资格、召集人的资格、表决程序以及 ...

Core Viewpoint - The company acknowledges that drug research and development is significantly influenced by industry policies and market changes, highlighting the inherent risks associated with long cycles, high investments, and uncertainty in outcomes [2] Group 1: Drug Research and Development - The company is adjusting its drug research and development projects based on its own circumstances and external environmental factors [2] - Drug research projects that enter the registration process will have their progress disclosed through regular reports and temporary announcements [2]

分红方面，福安药业A股上市后累计派现6.88亿元。近三年，累计派现2.02亿元。 机构持仓方面，截止2025年9月30日，福安药业十大流通股东中，香港中央结算有限公司位居第八大流 通股东，持股498.04万股，相比上期减少47.00万股。 责任编辑：小浪快报 融券方面，福安药业12月29日融券偿还3.77万股，融券卖出500.00股，按当日收盘价计算，卖出金额 2225.00元；融券余量2.96万股，融券余额13.17万元，超过近一年90%分位水平，处于高位。 资料显示，福安药业(集团)股份有限公司位于重庆市渝北区黄杨路2号，成立日期2004年2月25日，上市 日期2011年3月22日，公司主营业务涉及主要从事抗生素原料药及制剂的研发、生产和销售。主营业务 收入构成为：制剂类56.60%，原料药及中间体39.44%，其他(补充)3.55%，药品经销及其他0.41%。 截至12月19日，福安药业股东户数4.26万，较上期增加9.61%；人均流通股22737股，较上期减少 8.77%。2025年1月-9月，福安药业实现营业收入13.15亿元，同比减少34.08%；归母净利润1.66亿元，同 比减少44.87%。 ...

Group 1 - The company has a cultivation license for cannabis in the United States but is not currently engaged in related operations [1] - The U.S. project company is not included in the company's consolidated financial statements [1] - Ongoing litigation regarding a stock buyback dispute is affecting the company's involvement in the U.S. project [1]

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - Fuan Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its product, Sertraline Hydrochloride Tablets, which is effective in treating depression, including cases with or without anxiety [1] Company Summary - Fuan Pharmaceutical's wholly-owned subsidiary, Ningbo Tianheng Pharmaceutical Co., Ltd., is responsible for the development and registration of Sertraline Hydrochloride Tablets [1] - The approval of this drug expands Fuan Pharmaceutical's product portfolio in the mental health treatment sector [1] Industry Summary - The approval of Sertraline Hydrochloride Tablets highlights the growing focus on mental health treatments within the pharmaceutical industry [1] - The drug is indicated for the treatment of depression, which is a significant area of need in healthcare, particularly for patients experiencing anxiety [1]

Core Viewpoint - Fuan Pharmaceutical has received a drug registration certificate for its product, Clomipramine Hydrochloride Tablets, from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - Fuan Pharmaceutical's wholly-owned subsidiary, Ningbo Tianheng Pharmaceutical Co., Ltd., has been granted a registration certificate for Clomipramine Hydrochloride Tablets [1] - The tablets are available in two specifications: 50mg and 100mg [1] Group 2: Product Information - Clomipramine Hydrochloride Tablets are indicated for the treatment of depression, effective for patients with or without anxiety [1]